Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT03772665
SeaSTAR
Safety and Efficacy of Emixustat in Stargardt Disease.
Type: Interventional
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: Yes
Inclusion
- Opening Date: 2018-11-07
- Closing Date: 2022-02-01
Criteria
Children: Yes
Adults: Yes
Funder Type: industry
HCP: Principal investigators
- Rigshospitalet, Copenhagen, Denmark
- Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany
- AOU Careggi - AOU Meyer Consortium, Firenze, Itlay
- RÉFÉRET National Hospital of Ophthalmology of Quinze-Vingts, Paris, France
- AOU Università degli Studi della Campania Luigi Vanvitelli (formerly known as AOU Seconda Università degli Studi di Napoli), Napoli, Italy
- Radboud university medical center, Nijmegen, Netherlands
- Moorfields Eye Hospital NHS Foundation Trust
- Nuffield Department of Clinical Neurosciences (NDCN) & Oxford Eye Hospital West Wing
HCP: Other investigators
Within ERN-EYE members
Principal investigators
Other investigators
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
